Law360, New York (October 05, 2012, 9:09 PM ET) -- The Federal Trade Commission has argued that its case over the legality of pay-for-delay settlements involving blockbuster drug Androgel is a strong candidate for high court review, but with two other petitions already pending before the justices in a separate case over the controversial patent deals, attorneys on Friday questioned the agency's position.
The FTC was the third party to seek certiorari over pay-for-delay after a pair of petitions from the defendants in a Third Circuit case over the drug K-Dur 20, which endorsed the FTC's...
FTC’s Androgel Case May Not Be Best To Tackle Pay-For-Delay
To view the full article, take a free trial now.
